Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.

Andreas Strasser(The Royal Melbourne Hospital), Senga Whittingham(The Royal Melbourne Hospital), David L. Vaux(The Royal Melbourne Hospital), Mary L. Bath(The Royal Melbourne Hospital), Jerry M. Adams(The Royal Melbourne Hospital), Suzanne Cory(The Royal Melbourne Hospital), A W Harris(The Royal Melbourne Hospital)
Proceedings of the National Academy of Sciences
October 1, 1991
Cited by 868Open Access

Abstract

The biological functions of the BCL2 gene were investigated in transgenic mice harboring human BCL2 cDNA under the control of an immunoglobulin heavy chain enhancer (E mu). Mice of a representative transgenic strain, E mu-bcl-2-22, had a great excess of B lymphocytes, immunoglobulin-secreting cells, and serum immunoglobulins, attributable to increased longevity of B-lineage cells. Pre-B and plasma cells as well as B cells exhibited prolonged survival in culture. Immunized animals produced an amplified and protracted antibody response. Within the first year of life, most mice spontaneously produced antibodies to nuclear antigens, and 60% developed kidney disease, diagnosed as immune complex glomerulonephritis. Thus E mu-bcl-2-22 mice constitute a transgenic model for a systemic autoimmune disease resembling the human disorder systemic lupus erythematosus.


Related Papers